The ASAM National Practice Guideline 2020 Focused Update Webinar – Individuals in the Criminal Justice System
Includes a Live Event on 09/10/2020 at 12:00 PM (EDT)
The ASAM National Practice Guideline 2020 Focused Update Webinar – Individuals in the Criminal Justice System
This webinar follows the ASAM National Practice Guideline 2020 Focused Update Fundamentals webinar, which outlines the new and updated recommendations in the 2020 Focused Update of the National Practice Guideline for the Treatment of Opioid Use Disorder.
A substantial proportion of persons in prisons, jails, drug courts, probation, parole, and who are criminally involved have opioid use disorder and related problems. The high concentration of at-risk individuals and conditions of incarceration can increase the risk of adverse consequences associated with drug use, including violence, medical and psychiatric co-morbidity, drug-related deaths, self-harm and suicide. Furthermore, treatment of OUD in CJ settings has all too often been sub-standard. For example, when individuals are released from incarceration without OUD treatment, they are at extreme risk of relapse overdose and death. This webinar will provide an overview of the new and updated recommendations and in-depth information on treating individuals in the criminal justice system from the ASAM National Practice Guideline.
Date: Thursday, September 10, 2020
Time: 12:00 pm ET / 11:00 am CT/ 9:00 am PT
Speaker(s): Sandra Springer, MD
By completing this webinar, you will be able to:
- Summarize the guideline’s treatment recommendations for individuals in the criminal justice system with OUD and discuss how they should be used in practice.
- Identify the fundamental components of an OUD patient assessment and diagnosis for individuals in the criminal justice system.
- Recognize the unique needs and treatment recommendations for individuals in the criminal justice system
Sandra Springer, MD is an Associate Professor of Medicine in the Department of Internal Medicine, Section of Infectious Diseases at the Yale School of Medicine. Dr. Springer is Board-Certified in Internal Medicine, Infectious Diseases and Addiction Medicine. In addition, she is the Director of the Infectious Disease Clinic at the Newington site of the VA Connecticut Healthcare System where she oversees the care of Veterans living with HIV (VLH). She graduated from Harvard University, then later received her Medical Degree from University of Massachusetts Medical School. She did her Internal Medicine Residency and Infectious Disease Fellowship at Yale School of Medicine. Dr. Springer has significant clinical and research experience with persons living with HIV disease (PLH) and those with comorbid substance use disorders (SUD). Her research has focused on evaluation of integration of SUD and HIV treatments. In particular, she has focused on medication treatment for opioid use disorder (OUD) (MOUD) and medication treatment for alcohol use disorders (AUD) to improve substance use relapse outcomes and HIV treatment outcomes, especially among those released from prison and jail. Dr. Springer has been continuously NIH funded for over 15 years. She has a K02 Independent Scientist Award from NIDA evaluating medication treatment for OUD (MOUD) interventions among PLH. Dr. Springer has been a buprenorphine provider since 2005, and performed the first evaluation of the use of buprenorphine to prevent relapse to opioid use and improve HIV viral suppression among PLH released from prison. She created and later validated a rapid opioid dependency screen (RODS) that quickly identifies if someone has a moderate to severe opioid use disorder (OUD) to quickly initiate MOUD. She has studied extended-release naltrexone (XR-NTX) as a PI on a 5 year NIAAA-funded R01 which used a RCT design to evaluate its effect on improving HIV viral suppression for PLH released from prison; and she was a PI on a NIDA-funded R01 within the Seek Test Treat and Retain (STTR) Criminal Justice System (CJS) consortium to evaluate the use of XR-NTX to improve HIV VS among PLH with OUD released from prison/jail. Dr. Springer was a working group member of the NIDA STTR consortium that harmonized outcomes across 23 NIDA-funded STTR studies involving PLH and those who are at risk for HIV. Additionally, she was co-I on 2 NIDA R01s (1) using Buprenorphine to improve HIV treatment outcomes among CJS-involved PLH with OUD in Washington, D.C.; and (2) implementing XR-NTX among PLH with OUD in Ukraine. She is currently co-PI on a 5-year R01 from NIDA evaluating the impact of HIV infection on immunologic, transcriptomic, and metabolomic signatures among PLH compared to those without HIV infection who are beginning MAT for OUD. She is a co-PI with Drs. Ho and Kluger at Yale for a NIDA funded R33/R61 that is specifically evaluating the impact of all forms of MAT on HIV persistence; and she is a co-I on a HEALing NIDA funded grant to combat Opioid addiction in NY State. She is also the contact PI of a new U01 from NCATS that will integrate ID and injectable buprenorphine in hospitalized patients. She also is a co-PI on a new Justice involved HEALing grant at the NYU site with Dr. Josh Lee from NIDA evaluating OUD medication treatment for criminal justice involved persons with OUD and co-PI with Dr. Ismene Petrakis for a VA COOP grant among 900 Veterans with OUD comparing injectable and sublingual buprenorphine. She is a member of IDSA and HIVMA’s expert panel to integrate ID and OUD, a NASEM committee member evaluating the integration of ID and OUD treatment and prevention in community settings nationally, and a member of the ASAM committee that provided updated recommendations for use of MOUD in 2020.
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NAADAC, the Association for Addiction Professionals
This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1222
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205
Continuing Education Credits (CEUs)
Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.
Maintenance of Certification (MOC)
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.
ABA Maintenance of Certification (MOC)
This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.
ABP Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.
ABIM Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
ABAM Transitional Maintenance of Certification (Tmoc)
Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.
American Board of Psychiatry and Neurology (ABPN)
Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.
Program Planning Committee, CME Committee, Medical Education Council (MEC)
In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM CME Committee Reviewer
Subhadeep Barman, MD, FASAM, FAPA - No Financial Disclosures
Faculty & Planning Committee Disclosures
Kyle M. Kampman, MD – Does Disclose: World Meds (Clinical Condition: Opioid Use Disorder): Consultant/Advisory Board
Marc Fishman, MD – Does Disclose: Alkermes (Clinical Condition: OUD): Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received
Tricia Wright, MD, MS, DFASAM – Does Disclose McKesson (Clinical Condition: Opioid use in pregnancy): Consultant/Advisory Board
Sandra Springer, MD – Does Disclose: Alkermes Inc (Clinical Condition: Substance Use Disorder) Consultant/Advisory/Board, reviewed research grants for young investigators Clinical Care Options INc (Clinical Condition: Infectious disease) Speaker/Honoraria (includes speakers bureau, symposia, and expert witness)
George Woody, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory/Board, Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) Indivior (Clinical Condition: opioid use disorders) Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) World Meds (Clinical Condition: Opioid Use Disorders) Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support)
Daniel Langleben, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory Board
Stephen A. Wyatt, DO, FAOAAM, FASAM (Chair) – No Financial Disclosure
Timothy Wiegand, MD, FACMT, FAACT, DFASAM – No financial Disclosures